The Role of Complement Activation in Atherosclerosis

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2004 Jul 20

PMID 15258311

Citations 33

Authors

Florin Niculescu

Horea Rus

Affiliations

Soon will be listed here.

Abstract

Atherosclerosis is a chronic inflammatory disease in which dyslipidemia, inflammation, and the immune system play an important pathogenetic role. A role in atherogenesis was demonstrated for monocyte/macrophages, complement system, and T-lymphocytes. Complement activation and C5b-9 deposition occurs both in human and experimental atherosclerosis. Complement C6 deficiency has a protective effect on diet-induced atherosclerosis, indicating that C5b-9 assembly is required for the progression of atherosclerotic lesions. The maturation of atherosclerotic lesions beyond the foam cell stage was shown to be strongly dependent on an intact complement system. C5b-9 may be responsible for cell lysis, and sublytic assembly of C5b-9 induces smooth muscle cell (SMC) and endothelial cell (EC) activation and proliferation. All these data suggest that activation of the complement system plays an important role in atherogenesis.

Citing Articles

Enhanced complement activation and MAC formation accelerates severe COVID-19.

Ellsworth C, Chen Z, Xiao M, Qian C, Wang C, Shamima Khatun M Cell Mol Life Sci. 2024; 81(1):405.

PMID: 39284944 PMC: 11405604. DOI: 10.1007/s00018-024-05430-w.

Emerging role of complement in COVID-19 and other respiratory virus diseases.

Xiao M, Ellsworth C, Qin X Cell Mol Life Sci. 2024; 81(1):94.

PMID: 38368584 PMC: 10874912. DOI: 10.1007/s00018-024-05157-8.

Unveiling Wide Spectrum Therapeutic Implications and Signaling Mechanisms of Valsartan in Diverse Disorders: A Comprehensive Review.

Kumar K, Rawat P, Kaur S, Singh N, Yadav H, Singh D Curr Drug Res Rev. 2023; 16(3):268-288.

PMID: 37461345 DOI: 10.2174/2589977515666230717120828.

Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden Mice.

Seidel F, Kleemann R, van Duyvenvoorde W, van Trigt N, Keijzer N, van der Kooij S Int J Mol Sci. 2022; 23(18).

PMID: 36142647 PMC: 9506266. DOI: 10.3390/ijms231810736.

Coagulation and complement: Key innate defense participants in a seamless web.

Pryzdial E, Leatherdale A, Conway E Front Immunol. 2022; 13:918775.

PMID: 36016942 PMC: 9398469. DOI: 10.3389/fimmu.2022.918775.

References

Christiansen V, Sims P, Hamilton K . Complement C5b-9 increases plasminogen binding and activation on human endothelial cells. Arterioscler Thromb Vasc Biol. 1997; 17(1):164-71. DOI: 10.1161/01.atv.17.1.164. View

Seifert P, Hansson G . Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J Clin Invest. 1989; 84(2):597-604. PMC: 548921. DOI: 10.1172/JCI114204. View

Patel S, Thelander E, Hernandez M, Montenegro J, Hassing H, Burton C . ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun. 2001; 286(1):164-70. DOI: 10.1006/bbrc.2001.5276. View

Yasojima K, Schwab C, McGeer E, McGeer P . Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001; 21(7):1214-9. DOI: 10.1161/hq0701.092160. View

Oksjoki R, Jarva H, Kovanen P, Laine P, Meri S, Pentikainen M . Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol. 2003; 23(4):630-6. DOI: 10.1161/01.ATV.0000057808.91263.A4. View

Chang M, Binder C, Torzewski M, Witztum J . C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A. 2002; 99(20):13043-8. PMC: 130583. DOI: 10.1073/pnas.192399699. View

Niculescu F, Rus H, Vlaicu R . Decay-accelerating factor regulates complement-mediated damage in the human atherosclerotic wall. Immunol Lett. 1990; 26(1):17-23. DOI: 10.1016/0165-2478(90)90170-u. View

Reynolds G, Vance R . C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med. 1987; 111(3):265-9. View

Morgan B, Dankert J, Esser A . Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol. 1987; 138(1):246-53. View

10.

Owens G . Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995; 75(3):487-517. DOI: 10.1152/physrev.1995.75.3.487. View

11.

Torzewski J, Torzewski M, BOWYER D, Frohlich M, Koenig W, Waltenberger J . C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998; 18(9):1386-92. DOI: 10.1161/01.atv.18.9.1386. View

12.

Gousseva N, Kugathasan K, Chesterman C, Khachigian L . Early growth response factor-1 mediates insulin-inducible vascular endothelial cell proliferation and regrowth after injury. J Cell Biochem. 2001; 81(3):523-34. DOI: 10.1002/1097-4644(20010601)81:3<523::aid-jcb1066>3.0.co;2-e. View

13.

Klouche M, Rose-John S, Schmiedt W, Bhakdi S . Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation. 2000; 101(15):1799-805. DOI: 10.1161/01.cir.101.15.1799. View

14.

Simionescu N, Vasile E, Lupu F, Popescu G, Simionescu M . Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol. 1986; 123(1):109-25. PMC: 1888161. View

15.

Tran G, Hodgkinson S, Carter N, Killingsworth M, Spicer S, Hall B . Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords. J Immunol. 2002; 168(9):4293-300. DOI: 10.4049/jimmunol.168.9.4293. View

16.

Klouche M, Gottschling S, Gerl V, Hell W, Husmann M, Dorweiler B . Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler Thromb Vasc Biol. 1998; 18(9):1376-85. DOI: 10.1161/01.atv.18.9.1376. View

17.

Pinckard R, Olson M, Giclas P, Terry R, Boyer J, ORourke R . Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest. 1975; 56(3):740-50. PMC: 301923. DOI: 10.1172/JCI108145. View

18.

Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J . Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol. 1998; 18(3):369-78. DOI: 10.1161/01.atv.18.3.369. View

19.

Tenaglia A, Peters K, Sketch Jr M, Annex B . Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J. 1998; 135(1):10-4. DOI: 10.1016/s0002-8703(98)70336-9. View

20.

Torzewski M, Torzewski J, BOWYER D, Waltenberger J, Fitzsimmons C, Hombach V . Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1997; 17(11):2448-52. DOI: 10.1161/01.atv.17.11.2448. View